Arvinas (ARVN) Accumulated Expenses (2017 - 2022)
Arvinas (ARVN) posted quarterly Accumulated Expenses of $30.2 million for Q1 2022, up 953.63% year-over-year from $2.9 million in Q1 2021, and up 30.74% quarter-over-quarter from $23.1 million in Q4 2021.
Arvinas (ARVN) Accumulated Expenses (2017 - 2022) Analysis & Trends
Arvinas' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $30.2 million for Q1 2022.
- In Q1 2022, Accumulated Expenses rose 953.63% year-over-year to $30.2 million; the TTM figure through Mar 2022 stood at $30.2 million (up 953.63% YoY), while the FY2021 annual figure was $23.1 million, up 22.22% from the prior year.
- Accumulated Expenses for Q1 2022 stood at $30.2 million, up from $23.1 million in the prior quarter.
- The five-year high for Accumulated Expenses was $30.2 million in Q1 2022, with the low at $1.7 million in Q1 2019.
- The 5-year median for Accumulated Expenses is $6.8 million (2020), against an average of $9.8 million.
- The sharpest annual moves came in 2021 and 2022: Accumulated Expenses tumbled 57.75% in 2021, then soared 953.63% in 2022.
- Arvinas' Accumulated Expenses stood at $4.0 million in 2018, then surged by 90.01% to $7.6 million in 2019, then soared by 148.59% to $18.9 million in 2020, then climbed by 22.22% to $23.1 million in 2021, then soared by 30.74% to $30.2 million in 2022.
- Business Quant data shows ARVN's Accumulated Expenses at $30.2 million in Q1 2022, $23.1 million in Q4 2021, and $13.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 30.20 Mn |
| Dec 31, 2021 | 23.10 Mn |
| Sep 30, 2021 | 13.77 Mn |
| Jun 30, 2021 | 13.47 Mn |
| Mar 31, 2021 | 2.87 Mn |
| Dec 31, 2020 | 18.90 Mn |
| Sep 30, 2020 | 12.14 Mn |
| Jun 30, 2020 | 2.98 Mn |
| Mar 31, 2020 | 6.78 Mn |
| Dec 31, 2019 | 7.60 Mn |
| Sep 30, 2019 | 3.68 Mn |
| Jun 30, 2019 | 4.00 Mn |
| Mar 31, 2019 | 1.74 Mn |
| Dec 31, 2018 | 4.00 Mn |
| Sep 30, 2018 | 1.78 Mn |
| Dec 31, 2017 | 3.55 Mn |